Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Royalty Pharma Plc Cl A (NQ: RPRX )

26.47 +0.04 (+0.15%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Royalty Pharma Plc Cl A

< Previous 1 2 3 Next >
Royalty Pharma Announces Inaugural Prize for Impact in Healthcare
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma to Acquire Royalty Interest in Geron’s RYTELO for $125 Million
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma Reports Third Quarter 2024 Results
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma and Syndax Pharmaceuticals Enter Into $350 Million Royalty Funding Agreement for Niktimvo
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma to Announce Third Quarter 2024 Financial Results on November 6, 2024
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma Declares Fourth Quarter 2024 Dividend
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement
Proceeds to support continued development and commercialization of Endocrine Rare Disease products, including the Yorvipath U.S. commercial launch, and general corporate purposes 
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma to Present at Morgan Stanley’s 22nd Annual Global Healthcare Conference
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma Reports Second Quarter 2024 Results
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma Appoints Molly Sawaya as Executive Vice President, Head of Human Capital
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma to Announce Second Quarter 2024 Financial Results on August 8, 2024
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma Declares Third Quarter 2024 Dividend
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma Announces Pricing of $1.5 Billion of Senior Unsecured Notes
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 Million
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
From Royalty Pharma plc; Cytokinetics
Via GlobeNewswire
Royalty Pharma to Present at Upcoming Investor Conferences
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma Reports First Quarter 2024 Results
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma to Acquire Royalty Interest in Sanofi’s Frexalimab
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma to Announce First Quarter 2024 Financial Results on May 9, 2024
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma Declares Second Quarter 2024 Dividend
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma to Present at TD Cowen’s 44th Annual Health Care Conference
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma Reports Q4 and Full Year 2023 Results
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma To Announce Fourth Quarter And Full Year 2023 Financial Results On February 15, 2024
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma Announces Dividend Increase
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma Highlights Accomplishments and Provides Business Update at 42nd Annual J.P. Morgan Healthcare Conference
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma to Present at the Evercore ISI 6th Annual HealthCONx Conference
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma and Teva Collaborate to Further Accelerate Olanzapine Lai Program
From Royalty Pharma plc
Via GlobeNewswire
Teva and Royalty Pharma Collaborate to Further Accelerate Olanzapine LAI Program
From Teva Pharmaceutical Industries Limited
Via Business Wire
Royalty Pharma Reports Third Quarter 2023 Results
From Royalty Pharma plc
Via GlobeNewswire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.